ADMA BIOLOGICS Business Summary

ADMA Biologics, Inc. (ADMA) is a vertically integrated biopharmaceutical company specializing in the development, manufacturing, and commercialization of specialty plasma-derived biologics for immune deficiencies and infectious diseases. The company generates revenue primarily through the sale of its three FDA-approved products: ASCENIV, its flagship high-titer IVIG therapy; Bivigam, an intravenous immune globulin for primary humoral immunodeficiency; and Nabi-HB, for hepatitis B immunity. ADMA's business model is anchored by an end-to-end supply chain that includes proprietary plasma collection centers and a sophisticated manufacturing facility, which recently transitioned to yield-enhanced production to drive significant margin expansion. In the competitive landscape, ADMA contends with global giants such as Takeda Pharmaceuticals, Grifols, S.A., and CSL Behring. While these competitors maintain larger market shares, ADMA differentiates itself through its patented microneutralization assay and a focus on high-margin, niche specialty biologics that address underserved patient populations. The company was co-founded by Adam S. Grossman and Dr. Jerrold B. Grossman, both of whom possess extensive pedigrees in the blood and plasma industry. Adam S. Grossman serves as President and CEO, bringing over 30 years of experience from roles at MedImmune and the American Red Cross, while Dr. Jerrold Grossman serves as Vice Chairman with over 45 years of industry expertise. The leadership team was recently strengthened by the appointment of Terry Kohler as Chief Financial Officer and Treasurer in February 2026, who previously held CFO roles at OptiNose and Verrica Pharmaceuticals. Kaitlin M. Kestenberg-Messina serves as Chief Operating Officer and Senior Vice President of Compliance, overseeing global operations and regulatory strategy. ADMA is backed by a robust board and institutional investor base, including Chairman Steven A. Elms of Aisling Capital, alongside significant holdings from BlackRock, The Vanguard Group, and Sachem Head Capital Management.